当前位置： SCI文献检索 > INTERNATIONAL JOURNAL OF ONCOLOGY期刊下所有文献 > Response to inhibition of smoothened in diverse epithelial cancer cells that lack smoothened or patched 1 mutations.

Response to inhibition of smoothened in diverse epithelial cancer cells that lack smoothened or patched 1 mutations.

Abstract：

:Hedgehog (HH) pathway Smoothened (Smo) inhibitors are active against Gorlin syndrome-associated basal cell carcinoma (BCC) and medulloblastoma where Patched (Ptch) mutations occur. We interrogated 705 epithelial cancer cell lines for growth response to the Smo inhibitor cyclopamine and for expressed HH pathway-regulated species in a linked genetic database. Ptch and Smo mutations that respectively conferred Smo inhibitor response or resistance were undetected. Previous studies revealed HH pathway activation in lung cancers. Therefore, findings were validated using lung cancer cell lines, transgenic and transplantable murine lung cancer models, and human normal-malignant lung tissue arrays in addition to testing other Smo inhibitors. Cyclopamine sensitivity most significantly correlated with high cyclin E (P=0.000009) and low insulin-like growth factor binding protein 6 (IGFBP6) (P=0.000004) levels. Gli family members were associated with response. Cyclopamine resistance occurred with high GILZ (P=0.002) expression. Newer Smo inhibitors exhibited a pattern of sensitivity similar to cyclopamine. Gain of cyclin E or loss of IGFBP6 in lung cancer cells significantly increased Smo inhibitor response. Cyclin E-driven transgenic lung cancers expressed a gene profile implicating HH pathway activation. Cyclopamine treatment significantly reduced proliferation of murine and human lung cancers. Smo inhibition reduced lung cancer formation in a syngeneic mouse model. In human normal-malignant lung tissue arrays cyclin E, IGFBP6, Gli1 and GILZ were each differentially expressed. Together, these findings indicate that Smo inhibitors should be considered in cancers beyond those with activating HH pathway mutations. This includes tumors that express genes indicating basal HH pathway activation.

journal_name

Int J Oncol

journal_title

International journal of oncology

authors

Galimberti F,Busch AM,Chinyengetere F,Ma T,Sekula D,Memoli VA,Dragnev KH,Liu F,Johnson KC,Guo Y,Freemantle SJ,Andrew AS,Greninger P,Robbins DJ,Settleman J,Benes C,Dmitrovsky E

doi

10.3892/ijo.2012.1599

subject

Has Abstract

pub_date

2012-11-01 00:00:00

pages

1751-61

issue

eissn

1019-6439

issn

1791-2423

journal_volume

pub_type

杂志文章

在线工具

Response to inhibition of smoothened in diverse epithelial cancer cells that lack smoothened or patched 1 mutations.